<DOC>
	<DOCNO>NCT02609893</DOCNO>
	<brief_summary>This project randomize trial two strategy treat person genotype 1 HCV currently inject drug ( PWIDs ) daily regime ledipasvir-sofosbuvir ( LDV-SOF ) 8 week . The study enroll 30 participant assess feasibility acceptability treat active PWIDs HCV LDV-SOF modify directly observe therapy ( mDOT ) versus unobserved dosing , motivational interviewing base adherence support ; assess in-depth , semi-structured qualitative interview , challenge time intensity require mDOT unobserved dosing intervention , identify key factor affect treatment adherence .</brief_summary>
	<brief_title>Pilot Treatment Prevention HCV Among Persons Who Actively Inject Drugs</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>1 . ≥18 year age ; 2 . 2 consecutive positive HCV RNA test least 6 month estimate date infection ; 3 . HCV genotype 1 ; 4 . HCV RNA &lt; 6 million copy Roche TaqMan Assay 5 . No evidence hepatic cirrhosis ( determine two index : Fib4 &lt; 3.25—an accurate test detect cirrhosis base age , AST , ALT platelets [ sensitivity/specificity 76100/8291 % ] , confirm fibrosiscirrhosis index ( FCI ) &lt; 1.25 base ALT , bilirubin , albumin platelet [ sensitivity/specificity 86/100 % ] ) ; 6 . Drug injection past 30 day selfreport physical exam evidence injection drug use ( e.g . track mark ) , 7. inject others past 12 month selfreport ; 8 . Lab value within acceptable range ( platelet &gt; 50,000 , creatinine clearance CockroftGault &gt; 30mL/min , hemoglobin &gt; 10g/dL , INR &lt; 1.5 x upper limit normal ( ULN ) unless stable anticoagulant regimen know hemophilia , AST/ALT &lt; 10 x ULN ) ; 9 . Able speak English ; 10 . No plan leave San Francisco area least 9 month either live work San Francisco , travel San Francisco least weekly ; 11. woman childbearing age , pregnancy test negative , actively nursing , agree use birth control treatment ( although LDVSOF `` B '' rating , consistent know evidence harm , treatment urgent patient err side caution ) . 1 . HIV+ rapid test pool viral load ; 2 . HBV surface antigen + ; 3 . Nondefinitive HCV genotype result ; 4 . Previously receive treatment HCV ( interferon , ribavirin , DAA ) ; 5 . Taking medication affect pharmacokinetics LDVSOF ( protonpump inhibitor , anticonvulsant [ phenobarbital , phenytoin , carbamazepine , oxcarbazepine ] , rifamycins , rosuvastatin , herb [ St. John 's wort , silymarin , echinacea ] ) ; 6 . History follow : 1 . Current gastrointestinal disorder postoperative condition could interfere absorption study drug 2 . History hepatic decompensation ( i.e. , ascites , encephalopathy variceal hemorrhage ) 3 . History solid organ bone marrow transplantation . 4 . Current treatment cancer 7 . Chronic liver disease non HCV reason , except iron overload ( e.g. , Wilson 's disease , alfa 1 antitrypsin deficiency , cholangitis ) ; 8 . Use prohibit concomitant medication describe Section 5.2 within 21 day Day 1 visit ; 9 . Known hypersensitivity LDV , SOF , metabolites , formulation excipients . 10 . No condition preclude study involvement determine PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HCV</keyword>
</DOC>